Critical Reviews in Immunology最新文献_第8页

Integrated bioinformatics analysis to identify a novel four-gene prognostic model of breast cancer and reveal its association with immune infiltration 综合生物信息学分析鉴定一种新的四基因乳腺癌预后模型并揭示其与免疫浸润的关系

4区医学

Critical Reviews in Immunology Pub Date : 2023-01-01 DOI: 10.1615/critrevimmunol.2023050829

Yunhua Zhu, Junjie Luo, Yifei Yang

引用次数: 0

Preface Part 1: Immune Checkpoint Inhibitors and Autoimmunity. 前言第1部分:免疫检查点抑制剂和自身免疫。

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.v42.i3.10

Vipin Kumar, Benjamin Bonavida

引用次数: 0

The Role of Checkpoint Inhibitors in Autoimmune Diseases: Similarities and Differences Compared with Cancer. 检查点抑制剂在自身免疫性疾病中的作用:与癌症的异同

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2023047303

Kawaljit Kaur, Po-Chun Chen, Meng-Wei Ko, Anahid Jewett

{"title":"The Role of Checkpoint Inhibitors in Autoimmune Diseases: Similarities and Differences Compared with Cancer.","authors":"Kawaljit Kaur, Po-Chun Chen, Meng-Wei Ko, Anahid Jewett","doi":"10.1615/CritRevImmunol.2023047303","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2023047303","url":null,"abstract":"Programmed cell death-1 (PD-1) immunoinhibitory receptor expression is found on T cells, B cells, natural killer (NK) cells, and myeloid cells. Upon activation of T cells through peptide-major histocompatibility complex (MHC) engagement of the T cell receptor and costimulatory signaling, checkpoints including PD-1 are activated to regulate T cells. Since decreased expression of PD-1 in mice model was found to be associated with breakdown of peripheral tolerance, and demonstrated autoimmune disease characteristic, this receptor may be important therapeutic target for autoimmunity. In addition, decreased NK cell numbers and cytotoxicity in peripheral blood and altered expression of activating receptors and cytokine secretion of NK cells was seen in autoimmune disease patients. Therefore, in this review we discuss the relevance of PD-1 function in NK and T cells in autoimmunity, and demonstrate similarities and differences of its function in autoimmune diseases and cancer. Thus, PD-1 can be targeted to treat each disease entity accordingly. In cancer, the function of PD-1 can be blocked in order to enhance immune activation, whereas in autoimmune diseases it can be enhanced to block heightened immune function. However, we are far from understanding the exact functioning of this receptor in a complex tissue microenvironment, and further studies are required to establish its function at different stages of the disease, and at different stages of the maturation of immune effectors.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9282962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the V-Type Immunoglobulin Domain-Containing Suppressor to T Cell Activation (VISTA) with Agonist Monoclonal Antibodies in Autoimmunity. 在自身免疫中使用激动剂单克隆抗体靶向含v型免疫球蛋白域抑制因子T细胞活化(VISTA)

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2023047591

Megan Jung, Benjamin Bonavida

{"title":"Targeting the V-Type Immunoglobulin Domain-Containing Suppressor to T Cell Activation (VISTA) with Agonist Monoclonal Antibodies in Autoimmunity.","authors":"Megan Jung, Benjamin Bonavida","doi":"10.1615/CritRevImmunol.2023047591","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2023047591","url":null,"abstract":"The recognition of self-antigens by the T-cell immune system can results in autoimmunity. Current treatments of autoimmunity include non-steroid anti-inflammatory drugs and treatments aimed to control the immune system directly. Additionally, inhibiting signaling pathways that encourage T cell activation are promising strategies to help increase self-tolerance and control the inflammatory immune response. Despite the many treatments available, there are still great risks that accompanies each therapy; therefore, the shift towards immune checkpoint therapy is promising as it specifically targets the activated autoimmune T cells. In contrast to cancer, immune check point inhibitors (ICIs) for autoimmune treatment are attractive targets for the amplification of inhibitory functions of autoimmune T cells. A particular protein of interest for autoimmune therapy is the immune checkpoint protein V-type immunoglobin domain-containing suppressor of T cell activation (VISTA) or programmed dealth-1 homolog (PD-1H) of the B7 family. VISTA acts as both a ligand [on antigen presenting cells (APCs) and other cells] and as a receptor (on T cells). It functions as an immuno-suppressor by decreasing T cell proliferation, balancing the T cell/T regulatory cells (Tregs) ratio, and inhibiting cytokine production and inflammation. For the treatment of autoimmunity, an agonist anti-VISTA mAb is needed to interact and activate the inhibitory intracellular signaling pathways that result in the inactivation of the autoimmune T cells. New developments such as VISTA.cartilage oligomeric matrix protein (VISTA.COMP) and anti-human VISTA (anti-hVISTA) mAbs 7E12 and 7GF are potential drug candidates to help downregulate autoimmune responses and reduce the inflammatory states of patients with autoimmunity.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9410566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autoimmune Skin Diseases and Immune Checkpoint Inhibitors. 自身免疫性皮肤病和免疫检查点抑制剂。

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2023047032

Davide Fattore, Luca Potestio, Lucia Genco, Cecile Pages, Ariadna Ortiz, Gabriella Fabbrocini, Vincent Sibaud

{"title":"Autoimmune Skin Diseases and Immune Checkpoint Inhibitors.","authors":"Davide Fattore, Luca Potestio, Lucia Genco, Cecile Pages, Ariadna Ortiz, Gabriella Fabbrocini, Vincent Sibaud","doi":"10.1615/CritRevImmunol.2023047032","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2023047032","url":null,"abstract":"Immune system escape is one of the major strategies required for cancer growths. In this scenario, the advent of immune checkpoint inhibitors (ICIs) revolutionized the landscape of treatment options for tumors. Despite their wide use, these agents are associated with a unique spectrum of toxicities known as immune-related adverse events (irAEs). IrAEs are cause of treatment suspension (up to 60% of all causes of treatment interruption) and potentially impact on patients' quality of life. These toxicities are the main limitations on the use of these innovative drugs. IrAEs are peculiar, due to the mechanism of actions of ICIs, and any body organs may be involved (skin, thyroid, colon, lungs, in particular). Thus, the management often requires a multidisciplinary approach. The aim of this manuscript is to review current literature on autoimmune skin diseases described in association with ICIs (i.e., vitiligo, lupus erythematosus, vasculitis, morphea/scleroderma, alopecia areata, bullous pemphigoid, dermatomyositis), in order to provide a comprehensive overview for the physician.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9282961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microbiota-Specific Foxp3+ Regulatory T Cells Could Control Pathological T Helper Responses. 微生物特异性Foxp3+调节性T细胞可控制病理性T辅助反应。

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2022046412

David Usharauli, Tirumalai Kamala

引用次数: 0

Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management. 继发于免疫检查点抑制剂的皮肤免疫相关不良事件及其处理。

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2023046895

J Pach, J S Leventhal

{"title":"Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.","authors":"J Pach, J S Leventhal","doi":"10.1615/CritRevImmunol.2023046895","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2023046895","url":null,"abstract":"Immune checkpoint inhibitors (CPIs) are highly effective in the treatment of various cancers. Immunotherapy enhances antitumor activity by relieving inhibition of T cells responsible for immune surveillance. However, overactivation of T cells leads to immune-related adverse events (irAE), of which cutaneous adverse events are the most common. Examples include pruritus and maculopapular eruption most commonly, psoriasis and bullous dermatoses less commonly, and, rarely, severe, life-threatening eruptions such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. Many of these are autoimmune in nature, and these may present de novo or as recurrence of pre-existing disease. In order to maximize the therapeutic potential of CPIs, it is essential to recognize and effectively manage cutaneous irAE, which can otherwise lead to treatment interruption or discontinuation. This review summarizes the presentation and management of dermatologic adverse events secondary to immune dysregulation as a result of immune checkpoint inhibitor therapy, including the most common (maculopapular eruption, pruritus, lichenoid dermatitis, and vitiligo), less common (psoriasis, bullous pemphigoid, erythema multiforme, eczematous dermatitis, alopecia areata, and granulo-matous and neutrophilic dermatoses), and severe (acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS], and Stevens-Johnson syndrome or toxic epidermal necrolysis [SJS/TEN]), as well as exacerbation of pre-existing cutaneous autoimmune disease (subacute cutaneous lupus erythematosus, dermatomyositis, eosinophilic fasciitis, leukocytoclastic vasculitis, and scleroderma-like reaction).","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9410561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective. 使用自身抗体诊断由免疫检查点抑制剂引发的全身自身免疫疾病:临床观点

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2023047272

Alejandra Flores-Chávez, Pilar Brito-Zerón, Soledad Retamozo, Samuel Bitoun, Benjamin A Fisher, David Liew, Karijn Suijkerbuijk, Katerina Chatzidionysiou, María Suárez-Almazor, Olivier Lambotte, Xavier Mariette, Manuel Ramos-Casals

{"title":"Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective.","authors":"Alejandra Flores-Chávez, Pilar Brito-Zerón, Soledad Retamozo, Samuel Bitoun, Benjamin A Fisher, David Liew, Karijn Suijkerbuijk, Katerina Chatzidionysiou, María Suárez-Almazor, Olivier Lambotte, Xavier Mariette, Manuel Ramos-Casals","doi":"10.1615/CritRevImmunol.2023047272","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2023047272","url":null,"abstract":"Immunotherapies, such as immune checkpoint inhibitors (ICIs), have significantly advanced the treatment of cancer and other conditions. However, these therapies can also cause immune-related adverse events (irAEs), which are unintended side effects due to their effects on the immune system of the treated patient. These effects can be classified as organ-specific or systemic, with the latter being of particular interest due to their potential overlap with systemic autoimmune diseases (SADs). Autoantibodies, which are proteins produced by the immune system that react with self components, are often used to diagnose and classify SAD. However, the diagnostic value of autoantibodies in the context of systemic irAEs (sirAEs) triggered by ICIs is not well understood. This review aims to evaluate the diagnostic value of conventional autoantibodies in the identification and classification of sirAEs. A comprehensive search of the literature was conducted using the PubMed database, with a focus on articles published in the past 10 years. The results of the review suggest that, although autoantibodies can be useful in the diagnosis and classification of some SAD triggered by ICIs, there is a clear predominance of seronegative irAEs. The lack of traditional autoantibodies may suggest a unique mechanism for sirAEs and increases the already complex diagnostic approach of these manifestations, requiring evaluation by multidisciplinary teams with extensive experience in immunomediated diseases. Further research is needed to fully understand the diagnostic value of autoantibodies in this context and to determine the optimal approach for their detection and interpretation.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9410564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IL-18 Gene Promoter Polymorphisms are Involved in Periodontal Disease: A Meta-Analysis. IL-18基因启动子多态性与牙周病有关:一项荟萃分析

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2022047290

Preeti Shit, Nisha Sahu, Mohan Krishna Ghanta, Varsha Ahire, Ravindra Jagannath Jadhav, Neha Merchant, L V K S Bhaskar

{"title":"IL-18 Gene Promoter Polymorphisms are Involved in Periodontal Disease: A Meta-Analysis.","authors":"Preeti Shit, Nisha Sahu, Mohan Krishna Ghanta, Varsha Ahire, Ravindra Jagannath Jadhav, Neha Merchant, L V K S Bhaskar","doi":"10.1615/CritRevImmunol.2022047290","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2022047290","url":null,"abstract":"Microbial plaque that builds up in the gingival crevice area causes inflammation and leads to periodontal disease. Previous research has shown an association between interleukins with periodontitis. The association between interleukin-18 (IL-18) gene polymorphism and periodontitis risk was studied extensively, but the results are contradictory. The aim of this study is to find the association of two IL-18 promoter variants namely -607 C > A (rs1946518) and -137 G > C (rs187238), and the risk of chronic and aggressive periodontal disease by meta-analysis. The databases of PubMed, Medline, Web of Science, and Google Scholar were all explored to find the appropriate studies. The MetaGenyo software was used to calculate each analysis. Outcomes of the pooled analyses revealed significantly elevated risk for periodontitis for both polymorphisms. There is no significant heterogeneity between studies. No significant publication bias was observed. This meta-analysis provided the evidence of a link between IL-18 gene polymorphism in periodontitis.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9419966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Artificial Intelligence and Precision Medicine: Outcome of Immunotherapy in Hepatocellular Carcinoma. 人工智能和精准医学:肝细胞癌免疫治疗的结果。

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2022047261

Esube Theodros, Ganji Purnachndra Nagaraju

引用次数: 0